Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Randomized, Controlled, Single-Blind, Phase 2 Study in Treatment Resistant Major Depressive Disorder Patients Receiving Intranasal Esketamine (SpravatoTM) Over a 28-day Period Comparing Addition of Almond TherapyTM With Treatment-as-Usual

To see complete record on, please visit this link

Id: NCT05323019

Organisation Name: Zylorion Health

Overal Status: Not yet recruiting

Start Date: August 2022

Last Update: July 12, 2022

Lead Sponsor: Zylorion Health

Brief Summary: To examine the efficacy of Almond Therapy compared to Treatment as Usual when used in addition to an approved version of intranasal esketamine.

  • Treatment Resistant Major Depressive Disorder

Total execution time in seconds: 0.33708810806274